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Abstract
This guideline is endorsed by the specialty associations involved in the care of head and neck cancer patients in the
UK. This paper summarises the current imaging modalities in use for head and neck cancer evaluation. It highlights
their role in the management with recommendations on modality choice for each cancer subsite.
Recommendations
• Offer appropriate radiological imaging, based on tumour extent, site and local expertise, to stage tumours and
plan treatment for patients diagnosed with head and neck cancer. (G)
• Consider positron emission tomography combined with computed tomography (PET–CT) imaging if
conventional cross-sectional imaging identifies no primary site. (R)
• Offer PET–CT imaging 12 weeks after non-surgical treatment to detect residual disease. (R)
Introduction
Imaging in head and neck cancer has developed
enormously over the last few decades. Advanced
cross-sectional imaging modalities allow accurate
staging of disease and contribute significantly to man-
agement decisions and prognosis. As a core member of
a multidisciplinary team, the radiologist has a key role
in presenting relevant multi-modality findings that
define disease extent, help with surveillance and high-
light pertinent co-morbidities.1 This approach also aids
pre-treatment counselling and patient consent.
Prior to imaging, the primary site and the presence
or absence of neck metastases of a head and neck
cancer has often been established clinically and it is
not unusual for a histological diagnosis to have been
secured from a representative biopsy. Therefore, the
primary role of radiology is in accurately staging
the full extent and distant spread of disease with the
current tumour–node–metastasis (TNM) system, with
an emphasis on features that will influence surgical or
non-surgical treatment options.
The areas that radiological assessment should focus
on are:
• Local extent of the primary tumour
• Spread to locoregional cervical lymph nodes
• Detection of metastatic disease precluding cure
and synchronous primary tumours of the lung
and upper aero-digestive tract.
Imaging modalities
Computed tomography (CT)
Contrast-enhanced CT is the mainstay for imaging
primary disease. It is widely available and established
in practice. It incurs a significant radiation penalty
and iodinated contrast medium is contraindicated in
those with severe renal impairment. Conventionally,
centres would image the neck and chest at presentation
from the skull base to below the diaphragm.
Spatially good but at a radiation cost, CT provides
limited soft tissue resolution. Bone detail such as
with mandibular or skull base involvement is a major
strength. Modern multislice, slip-ring CT detector tech-
nology rapidly acquires images without movement
artefact as potential head and neck cancer patients
may have difficulty with breathing, swallowing secre-
tions and lying flat. Multiplanar and volume rendered
images are easily reconstructed. Contrast-enhanced
CT allows opacification of vascular structures whilst
tumours generally tend to be slower to enhance with
a reduced wash out.
Magnetic resonance imaging (MRI)
Magnetic resonance imaging reflects biochemical
tissue characteristics and is largely influenced by
proton density and other in situ paramagnetic sub-
stances such as blood products and melanin content.
Alongside the permanent bore magnet, additional
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transient magnetic gradients allow the development of
an ever increasing array of sequences that are able to
reflect pathological processes from normal surrounding
tissues. Multiple manufacturers may have differing
terms for sometimes similar sequence parameters.
T1-weighted ‘anatomical’ images have excellent
spatial resolution, whilst T2-weighted images preferen-
tially highlight oedema and therefore pathology. A
short tau inversion-recovery (STIR) sequence retains
the positive attributes of a T2-weighted image and sup-
presses surrounding fat signal in normal or invaded
tissues to best depict abnormal tissue as a bright,
high signal. Magnetic resonance imaging has the
ability to dramatically improve tissue contrast reso-
lution when compared with CT and, in compliant
patients without contraindications, it is the imaging
modality of choice for defining the primary extent of
oral and oropharyngeal cancers. Detrimentally, when
compared with CT, scan times are much longer and
can vary from about 2–10 minutes for each sequence,
during which the patient must keep relatively still.
Intravenous gadolinium contrast agents allow static
and dynamic vascular assessments of a tumour and,
when combined with fat suppression techniques, this
can increase the conspicuity of occult pathology.
Dental amalgam can reduce the image quality both
for CT and MR imaging that makes interpretation
more challenging.
Positron emission tomography combined with CT
(PET–CT)
Positron emission tomography combined with CT
whole-body imaging uses various labelled tracers to
fuse conventional, anatomical CT images with a func-
tional ‘map’ of the disease process. This is conducted
on a single gantry at a single appointment. The com-
monest tracer is 18 fluoro-deoxyglucose, which is pref-
erentially transported and trapped into hypermetabolic
cancerous or inflamed tissues. It is detected with a
gamma camera array. The patient’s fasted baseline
glucose level should be measured and the isotope is
injected intravenously approximately 1 hour before
imaging. The patient refrains from talking or chewing.
Actual image acquisition takes about 30–45 minutes.
Modern scanner design accurately co-registers
metabolic tissue activity with its precise anatomical
location.
In 2013, the Royal College of Radiologists published
evidence-based guidelines for PET–CT use in head
and neck cancer. Evaluating the patient with malignant
cervical adenopathy from an unknown primary is one
of the main, up-front indications. Positron emission
tomography will detect an occult primary in approxi-
mately one third of cases. Positron emission tomog-
raphy combined with CT is also valuable in the
assessment of suspected recurrence of head and neck
cancer when there are extensive, confounding post-
treatment changes on conventional imaging modalities.
Its added benefit in routine surveillance following treat-
ment is still being assessed. Along with other modal-
ities, it has a role in staging malignant thyroid disease
including medullary thyroid carcinoma.
Ultrasound
Offered as part of a modern one-stop service, ultra-
sound, alongside fine needle aspiration cytology,
allows rapid imaging assessments for those with an
undiagnosed neck lump or suspected metastatic
disease in the neck. This technique can be notoriously
operator dependent, but has no detrimental patient
effects. Following slide preparation, best cytological
practice recommends prompt adequacy assessments
and, ideally, the cytologist should be onsite for diag-
nostic advice. In reality, a shortage of radiology and
histopathological input makes such universal service
developments difficult.
Ultrasonography comfortably delineates thyroid
pathology and can detect occult pathological nodes
(necrosis, microcalcification, etc.) that may feel clinic-
ally normal in size. A normal node should remain ovoid
in shape with a short axis diameter less than 10 mm
with a preserved echogenic hilum. Retropharyngeal
and superior mediastinal nodes cannot be assessed
with this modality.
Current doctrine dictates that clinically and radio-
logically N0 disease from high-risk primary sites is
presumed to have small volume nodal micrometastasis
that routinely requires prophylactic first-line treatment
as no available tests can guarantee a true pathological
N0 status.
Fluoroscopy
There are a variety of scenarios when contrast swallows
and fluoroscopy are used in head and neck cancer,
although the availability of local expertise can be vari-
able. Contrast swallows can be used to assess the length
of a malignant proximal oesophageal stricture, while
the risk of airway aspiration or penetration is dynamic-
ally assessed by videofluoroscopy. Alternative, non-
oncological causes for dysphagia such as a pharyngeal
pouch may be diagnosed. Water soluble contrast
studies are advised when the risk of aspiration is
high, for instance, following recurrent chest infections
or diminished pharyngeal sensory/motor function
after surgery or radiation. The integrity of a surgical
anastomosis or the tract of an entero-cutaneous fistula
can also be well evaluated. These studies are often
jointly performed with a speech and language therapist
to facilitate decision making and may improve func-
tional outcomes.
Chest imaging
With common aetiological factors, patients with head
and neck cancer have higher incidences of synchronous
and metachronous primary lung tumours that may be
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disseminated at presentation. At staging, CT imaging of
the thorax is routinely advised.
The most common protocol for patients with a head
and neck cancer will therefore be to image the primary
site by either contrast-enhanced CT or magnetic reson-
ance imaging (MRI), perform CT imaging of the chest
and PET–CT for the unknown primaries.
Specific tumour sites
This section deals with specific tumour sites and high-
lights areas where radiological evaluation is particular-
ly important and often difficult.
Oral cavity
Preferred imaging modality: MRI
Tongue tumours are routinely evaluated with MRI to
aid treatment choices and prognosis. Early or advanced
cancers of the buccal mucosa, retromolar trigone, palatal
and floor of mouth are more difficult to evaluate reliably
by imaging alone and good clinical correlation is essen-
tial. Perineural and marrow involvement is best defined
at MRI.
In an attempt to avoid osteoradionecrosis, orthopan-
tomograms are still requested to proactively treat dental
caries and peri-apical disease.
Oropharynx
Preferred imaging modality: MRI
Small or subclinical primaries in the tonsil and
tongue base that often present with cervical lymph-
adenopathy can be difficult to identify with all forms
of imaging including PET–CT. These tumours are
often best evaluated at MRI with STIR sequences and
often, may only be localised retrospectively after exam-
ination and biopsy under anaesthesia. Extension of
mucosal tumours into the adjacent structures and
neck spaces is well depicted with MR imaging.
Nasopharynx
Preferred imaging modality: MRI
Nasopharyngeal tumours commonly present at an
advanced stage with palpable nodal neck disease.
Magnetic resonance imaging allows accurate classifica-
tion of the primary site and nodal disease as per the
TNM classification, based on disease extent.
Hypopharynx
Preferred imaging modality: MRI
In those patients who have difficulty with swallow-
ing, aspiration or breathing when supine, a CT scan
will need to be strongly considered.
Larynx
Preferred imaging modality: MRI
Disease at the level of the vocal cords presents
early with dysphonia and is well localised. Imaging is
often unnecessary for T1 disease unless extralaryngeal
disease, cartilage involvement, nodal metastasis or
chest pathology is suspected. MRI with contrast is the
gold standard for depiction of cartilage involvement.
Recommendations
• Offer appropriate radiological imaging, based
on tumour extent, site and local expertise, to
stage tumours and plan treatment for patients
diagnosed with head and neck cancer (G)
• Consider PET–CT imaging if conventional
cross-sectional imaging identifies no primary
site (R)
• Offer PET–CT imaging 12 weeks after
non-surgical treatment to detect residual
disease (R)
Salivary glands
Malignant salivary glands neoplasms are a very
heterogenous group of tumours, where tumour behav-
iour and prognosis is dictated by the histology.
Ultrasound techniques have a significant role to play
in assessing the parenchymal mass, local adenopathy
and guiding biopsies. Perineural or skull base involve-
ment often requires a combined multi-modality CT
and MR approach. The best imaging modality may
be guided by site-specific characteristics such as
respiratory motion artefact.
Sinuses
MRI with contrast is the modality of choice to assess
surgical resectability issues around intracranial and
orbital disease spread. Skull base involvement usually
requires a complementary CT study.
Post-operative imaging
The choice of imaging in the post-operative scenario is
determined by the specific clinical question posed.
Complications are frequent with difficult head and
neck resections. When the specific question is over
potential residual or recurrent disease, following
either surgery or chemoradiotherapy, the choice for
baseline imaging mainly falls between a contrast CT
of the neck and chest and a timely PET–CT study.
As an exception, MRI has a large role to play specific-
ally for nasopharyngeal, sinonasal and skull base
tumour follow up.2 Early detection of residual disease
is vital to planning further curative attempts. The
timing of the scan is important. Dedicated CT gives
better resolution and anatomical detail at the primary
site as well as detecting subcentrimetre early metastatic
disease in the lungs. Obliteration of fat planes and ana-
tomical distortions makes interpretation difficult. A
negative, normal PET–CT 12 weeks post-treatment
likely offers the best prognostic reassurance currently.3
PET–CT fails to reliably distinguish inflammatory
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elements from malignant foci. Ultrasound guided pro-
cedures still have a role to play in sampling in-
determinate, persistent enlarged cervical nodes.
Key points
• Accurate image interpretation and staging heavily
influences optimal treatment strategies
• Contrast-enhanced computed tomography of the
skull base, neck and chest is ubiquitous in nature,
readily available and the workhorse for routine
tumour–node–metastasis staging of head and neck
cancers
• Positron emission tomography combined with com-
puted tomography is of proven diagnostic benefit
when searching for the unknown primaries, when
conventional imaging is non-informative
• In compatible patients, magnetic resonance imaging
has superior soft tissue characterisation at several
primary sites including oropharynx, nasopharynx/
skull base and sinuses that greatly aid surgical plan-
ning and resections
• Ultrasound image guided diagnostic fine needle and
core biopsies are well established and cost-effective
in the context of good cytological/histological support
• In certain instances, multi-modality approaches are
complementary to each other but should not adverse-
ly impact on the speed of the diagnostic pathway.
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